Predictors of loss of asthma control in the Phase 2a INCONTRO trial: A post-hoc analysis

被引：0

作者：

Palmer, Robert ^{[1
]}

Almquist, Joachim ^{[1
]}

Hashemi, Mahdi ^{[2
]}

Taib, Ziad ^{[2
]}

Necander, Sofia ^{[3
]}

Korsback, Katarina ^{[3
]}

Aurell, Malin ^{[4
]}

Asimus, Sara ^{[1
]}

Delaney, Stephen ^{[5
]}

Pardali, Katerina ^{[6
]}

Gustafson, Per ^{[7
]}

Sethi, Tariq ^{[3
]}

Keeling, David ^{[8
]}

Psallidas, Ioannis ^{[3
]}

机构：

[1] AstraZeneca, R&D, Clin Pharmacol & Safety Sci, Clin Pharmacol & Quantitat Pharmacol, Gothenburg, Sweden

[2] AstraZeneca, BioPharmaceut R&D, Data Sci & AI, BioPharma Early Biometr & Stat Innovat, Gothenburg, Sweden

[3] AstraZeneca, BioPharmaceut R&D, Clin Dev, Early RIA, Gothenburg, Sweden

[4] AstraZeneca, BioPharmaceut R&D, Clin Operat, Late RIA, Gothenburg, Sweden

[5] AstraZeneca, BioPharmaceut R&D, Biosci, Early RIA, Gothenburg, Sweden

[6] AstraZeneca, R&D, Precis Med BioPharmaceut, Gothenburg, Sweden

[7] AstraZeneca, BioPharmaceut, Global Med Resp, Gothenburg, Sweden

[8] AstraZeneca, BioPharmaceut R&D, Early RIA, Gothenburg, Sweden

来源：

关键词：

Exacerbation; Biomarkers; Asthma;

D O I：

10.1183/13993003.congress-2020.2278

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

2278

引用

页数：2